Sign Out
New or Worsened Emotional or Behavioural Problems: Particularly in the first few weeks or when doses are adjusted, a small number of patients taking drugs of this type may feel worse instead of better. They may experience new or worsened feelings of aggression, agitation, hostility, anxiety, impulsivity, or thoughts about suicide, self-harm or harm to others.
Suicidal thoughts and actions can occur in any age group but may be more likely in patients 18 to 24 years old. Should this happen, consult the doctor immediately. Close observation by a doctor is necessary in this situation. Do not discontinue the medication without supervision. It may be more likely to think like this if there had been previous thoughts about self-harm.
It may be helpful to tell a relative or close friend about being depressed and ask them to read the patient information leaflet. They may be asked to inform if they suspect worsening depression or anxiety, or if they are worried about changes in behaviour.
Taking APO-DESVENLAFAXINE may increase the risk of experiencing sexual problems, which may continue after APO-DESVENLAFAXINE has been discontinued. Tell the doctor if experiencing symptoms such as sexual dysfunction, ejaculation disorder (in men), ejaculation failure (in men), libido decrease or anorgasmia (difficulty reaching orgasm).
Bone Fracture Risk: Taking APO-DESVENLAFAXINE may increase the risk of breaking a bone if elderly or with osteoporosis or with other major risk factors for breaking a bone. Take extra care to avoid falls especially if dizzy or with low blood pressure.
Other Medicines and Nutritional or Herbal Supplements: Tell the doctor or pharmacist if taking or have recently taken any other medicines, including medicines obtained without a prescription.
Avoid taking APO-DESVENLAFAXINE with other medicines containing venlafaxine or desvenlafaxine.
The health professional will decide if APO-DESVENLAFAXINE can be taken with other medicines.
Angle-Closure Glaucoma: APO-DESVENLAFAXINE can cause an acute attack of glaucoma. Having the eyes examined before taking APO-DESVENLAFAXINE could help identify if at risk of having angle-closure glaucoma. Seek immediate medical attention if experiencing: eye pain; changes in vision; swelling or redness in or around the eye.
Sexual Dysfunction: Serotonin-norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction. There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SNRIs.
Abnormal Bleeding/Haemorrhage: SNRIs may increase the risk of postpartum haemorrhage.
Other Medical Problems: Before using APO-DESVENLAFAXINE, tell the doctor or pharmacist if: taking other medicines, herbal or nutritional supplements (see as previously mentioned and Interactions); with a history of high blood pressure; with a history of heart problems; with a narrowing or blockage of the gastrointestinal tract (oesophagus, stomach, or small or large intestine); with a history of fits (seizures); with a history of low sodium levels in the blood; with a bleeding disorder or with low platelets; with a recent bone fracture or with osteoporosis or risk factors for osteoporosis; with a history of high cholesterol; with a history or family history of mania or bipolar disorder; with kidney problems; pregnant or thinking about becoming pregnant, or if breastfeeding. If any of these conditions are applicable, talk with the doctor before taking APO-DESVENLAFAXINE.
Serotonergic psychiatric drugs should not be started in a patient receiving linezolid. Wait until 24 hours after the last dose of linezolid before starting serotonergic psychiatric drugs.
Driving and Using Machines: Do not drive or operate any tools or machines until it is known how APO-DESVENLAFAXINE affects. Do not drive or operate any tools or machines if APO-DESVENLAFAXINE affects in a way that prevents from safely performing these operations. If there are any further questions on the use of this product, ask the doctor or pharmacist.
Use in Children: APO-DESVENLAFAXINE should not be used in children and adolescents under 18 years of age.
